OTS-412

DRUG3 trials

Sponsors

Bionoxx Inc.

Conditions

Healthy VolunteerTreatment-Refractory Solid Tumors

Early Phase 1

A Single-volunteer Study of Immune Response Following OTS-412 Vaccinia Virus Systemic Injection(Self-experiment)

CompletedNCT07302945

Bionoxx Inc.Healthy Volunteer

Start: 2022-01-04End: 2022-05-02Updated: 2025-12-26

Phase 1

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients

Not yet recruitingNCT07170592

Bionoxx Inc.Treatment-Refractory Solid Tumors

Start: 2027-01-01End: 2030-12-01Target: 24Updated: 2026-08-26

A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)

RecruitingNCT07190833

Bionoxx Inc.Treatment-Refractory Solid Tumors

Start: 2026-03-09End: 2030-12-01Target: 27Updated: 2026-08-26